Krishna Institute of Medical Sciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,344 Cr +39.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
KI

Krishna Institute of Medical Sciences Ltd

Q4 FY26Healthcare Services

Krishna Institute of Medical Sciences Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,075Cr
+34.9% YoY
+7.7% QoQ
Net profit
₹33Cr
−68.9% YoY
−36.5% QoQ
Margin
19%
−6 pp YoY
−1 pp QoQ

Krishna Institute of Medical Sciences Ltd Q4 FY26 key numbers

Revenue
Bangalore hospitals' occupancy expected to reach 35-40% by end of next financial year, with ARPOB stabilizing around INR 75,000 initially and improving over time.

As stated in Krishna Institute of Medical Sciences Ltd's Q4 FY26 earnings call transcript · published 24 May 2026. Reported figures, not investment advice.

Price₹782
Market cap₹33.7K Cr
P/E161.5

The short version

KIMS Hospitals expects steady expansion over the next 3 to 5 years with both Greenfield and Brownfield projects in Karnataka, Kerala, Tamil Nadu, Andhra Pradesh, and Telangana. The company expects a steady expansion over the next 3 to 5 years, aiming to maintain similar growth levels as in the past five years.

From Krishna Institute of Medical Sciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • KIMS Hospitals expects steady expansion over the next 3 to 5 years with both Greenfield and Brownfield projects in Karnataka, Kerala, Tamil Nadu, Andhra Pradesh, and Telangana.
  • New hospitals in Bangalore (Mahadevapuram, Electronic City) and Telangana (Kondapur, Kompally) are expected to ramp up and become EBITDA positive, contributing to volume-driven growth in the next 4-5 years.
  • IP and OP volumes grew by 15.4% and 25.4% respectively in FY '26, with sustained upward trends anticipated.
  • Bangalore hospitals' occupancy expected to reach 35-40% by end of next financial year, with ARPOB stabilizing around INR 75,000 initially and improving over time.
  • Telangana cluster anticipates healthy EBITDA growth of around 10%-12% in FY '27.

2 more points from Krishna Institute of Medical Sciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Krishna Institute of Medical Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company plans steady expansion, including both Greenfield and Brownfield projects, over the next 3-5 years.
  • Next 12-24 months focus on consolidating current hospitals and expanding margins.
  • Greenfield projects planned in Karnataka, Kerala, Tamil Nadu (1 new hospital), Andhra Pradesh, and Telangana.
  • Expansion involves adding more beds year-on-year; beds at Kondapur new facility to be commissioned in phases (400-500 beds in Phase 1, remaining 300 phased based on occupancy).
  • Remaining CAPEX of around INR 50-75 crores for Kondapur to be incurred in FY '28 and beyond.
  • Acquisitions of smaller hospitals (approx. 400-500 beds collectively) possible within next two quarters.

2 more points from Krishna Institute of Medical Sciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Krishna Institute of Medical Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant information related to expansions and acquisitions includes: - Ongoing and planned expansions in Karnataka, Kerala, Tamil Nadu, Andhra Pradesh, and Telangana with greenfield and brownfield projects. - Small acquisition opportunities totaling around 400-500 beds expected over the next two quarters.

2 more points from Krishna Institute of Medical Sciences Ltd's call on order book

Create a free account to keep reading this call

Krishna Institute of Medical Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Krishna Institute of Medical Sciences Ltd Q4 FY26 results — key figures

Krishna Institute of Medical Sciences Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,075797+34.9%998+7.7%
Operating profit (EBITDA)206198+4%199+3.5%
Operating margin19%25%-6 pp20%-1 pp
Profit before tax55134-59%69-20.3%
Net profit (PAT)33106-68.9%52-36.5%
EPS (₹)1.062.54-58.3%1.33-20.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹75 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Suven Life Sciences (Q4 FY26)

    The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

  • Invicta Diagnostic (Q4 FY26)

    Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…

  • KMC Speciality (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • Star Imaging (Q4 FY26)

    Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Krishna Institute of Medical Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Krishna Institute of Medical Sciences Ltd Q4 FY26 results?

KIMS Hospitals expects steady expansion over the next 3 to 5 years with both Greenfield and Brownfield projects in Karnataka, Kerala, Tamil Nadu, Andhra Pradesh, and Telangana. The company expects a steady expansion over the next 3 to 5 years, aiming to maintain similar growth levels as in the past five years.

What is Krishna Institute of Medical Sciences Ltd share price analysis?

Krishna Institute of Medical Sciences Ltd currently shows a neutral. The stock trades at a P/E of 161.5 with a market cap of ₹33,691 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krishna Institute of Medical Sciences Ltd planning capital expenditure?

The company plans steady expansion, including both Greenfield and Brownfield projects, over the next 3-5 years. - Next 12-24 months focus on consolidating current hospitals and expanding margins. - Greenfield projects planned in Karnataka, Kerala, Tamil Nadu (1 new hospital), Andhra Pradesh, and Telangana. - Expansion involves adding more beds year-on-year; beds at Kondapur new facility to be commissioned in phases (400-500 beds in Phase 1, remaining 300 phased based on occupancy). - Remaining CAPEX of around INR 50-75 crores for Kondapur to be incurred in FY '28 and beyond. - Acquisitions of smaller hospitals (approx.

Keep Krishna Institute of Medical Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.